Table Graph
      published meta-analysis   sensitivity analysis   studies

umifenovir (arbidol) in COVID-19 (hospitalized or not) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical improvementdetailed resultsChang Chen et al., 2020 (REV) 0.68 [0.40; 1.14] 0.68[0.40; 1.14]Chang Chen et al., 2020 (REV)10%236NAnot evaluable clinical improvement (7-day)detailed resultsChang Chen et al., 2020 (REV) 0.68 [0.40; 1.14] 0.68[0.40; 1.14]Chang Chen et al., 2020 (REV)10%236NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-27 08:20 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87 - treatments: 516 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons